Zentalis Pharmaceuticals
ZNTL
ZNTL
137 hedge funds and large institutions have $1.61B invested in Zentalis Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 39 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
3.37% less ownership
Funds ownership: 116.94% → 113.58% (-3.4%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less capital invested
Capital invested by funds: $2.32B → $1.61B (-$715M)
Holders
137
Holding in Top 10
4
Calls
$4.81M
Puts
$906K
Top Buyers
| 1 | +$18.8M | |
| 2 | +$8.93M | |
| 3 | +$7.7M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.17M |
| 5 |
Millennium Management
New York
|
+$5.19M |
Top Sellers
| 1 | -$25.4M | |
| 2 | -$21.7M | |
| 3 | -$10.2M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$9.02M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.47M |